Ionis Pharmaceuticals (NASDAQ:IONS) Shares Down 4.4% – Time to Sell?

Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) traded down 4.4% during mid-day trading on Thursday . The company traded as low as $58.11 and last traded at $58.6250. Approximately 1,365,232 shares traded hands during mid-day trading, a decline of 43% from the average daily volume of 2,400,945 shares. The stock had previously closed at $61.33.

Key Headlines Impacting Ionis Pharmaceuticals

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: The FDA approved ZANVASTRO (zilganersen) for pediatric and adult patients with Alexander disease, making it the first and only disease-modifying treatment for the ultra-rare, progressive neurological disorder. The approval could create a new commercial opportunity for Ionis and includes a priority review voucher, which may have additional strategic or financial value. ZANVASTRO FDA approval announcement
• Positive Sentiment: Analysts remain constructive following the approval. Needham reaffirmed its “buy” rating and set an $86 price target, while Barclays also maintained a buy recommendation. The analyst support signals confidence in ZANVASTRO’s launch potential and Ionis’ broader pipeline. Barclays maintains buy rating
• Neutral Sentiment: Ionis discussed its launch strategy for ZANVASTRO after the FDA decision. Investors are likely watching the size of the eligible patient population, pricing, reimbursement, commercial execution and the timing of revenue contributions. Ionis ZANVASTRO launch strategy transcript
• Negative Sentiment: A bearish Seeking Alpha analysis downgraded Ionis to “sell,” citing a series of unfavorable developments and concerns that may outweigh the near-term approval catalyst. Broader biotechnology sentiment was also affected by a failed Ultragenyx trial, adding volatility to the sector and weighing on Ionis despite its own regulatory success. Ionis bearish analysis

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Jefferies Financial Group dropped their price target on Ionis Pharmaceuticals from $113.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, July 9th. Barclays reduced their price objective on Ionis Pharmaceuticals from $115.00 to $90.00 and set an “overweight” rating for the company in a research note on Friday, July 10th. Royal Bank Of Canada decreased their target price on Ionis Pharmaceuticals from $100.00 to $85.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Wells Fargo & Company dropped their target price on Ionis Pharmaceuticals from $100.00 to $95.00 and set an “overweight” rating on the stock in a research report on Thursday, July 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a report on Friday, July 17th. Seventeen investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $94.20.

Ionis Pharmaceuticals Price Performance

The stock has a market capitalization of $9.65 billion, a PE ratio of -16.79 and a beta of 0.42. The company has a debt-to-equity ratio of 3.07, a current ratio of 7.89 and a quick ratio of 7.73. The stock’s fifty day moving average is $61.25 and its 200-day moving average is $70.56.

Insiders Place Their Bets

In other Ionis Pharmaceuticals news, Director Michael R. Hayden purchased 15,000 shares of the business’s stock in a transaction that occurred on Thursday, July 30th. The stock was purchased at an average price of $53.38 per share, for a total transaction of $800,700.00. Following the purchase, the director directly owned 19,000 shares in the company, valued at approximately $1,014,220. This trade represents a 375.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Eugene Schneider sold 26,000 shares of the company’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $81.05, for a total value of $2,107,300.00. Following the completion of the transaction, the executive vice president directly owned 77,114 shares of the company’s stock, valued at $6,250,089.70. The trade was a 25.21% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 225,163 shares of company stock valued at $17,711,191. Insiders own 1.81% of the company’s stock.

Institutional Trading of Ionis Pharmaceuticals

Several institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. raised its stake in shares of Ionis Pharmaceuticals by 72.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 652,518 shares of the company’s stock worth $19,686,000 after buying an additional 274,310 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Ionis Pharmaceuticals by 6.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 659,435 shares of the company’s stock valued at $19,895,000 after acquiring an additional 39,794 shares during the period. Focus Partners Wealth grew its stake in Ionis Pharmaceuticals by 30.1% in the 1st quarter. Focus Partners Wealth now owns 9,832 shares of the company’s stock valued at $297,000 after acquiring an additional 2,277 shares during the period. Franklin Resources Inc. acquired a new stake in Ionis Pharmaceuticals in the 2nd quarter valued at $220,000. Finally, Prudential Financial Inc. increased its holdings in Ionis Pharmaceuticals by 47.8% in the 2nd quarter. Prudential Financial Inc. now owns 9,254 shares of the company’s stock worth $341,000 after acquiring an additional 2,991 shares in the last quarter. 93.86% of the stock is owned by institutional investors and hedge funds.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.